These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 25347610)

  • 1. Acute and late toxicity after three-dimensional conformal image-guided radiotherapy for localized prostate cancer.
    Ingrosso G; Carosi A; Ponti E; Murgia A; di Cristino D; Barbarino R; Benassi M; Di Murro L; Giudice E; Bove P; Santoni R
    Cancer Invest; 2014 Dec; 32(10):526-32. PubMed ID: 25347610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study.
    Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M
    Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes.
    Patel N; Faria S; Cury F; David M; Duclos M; Shenouda G; Ruo R; Souhami L
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):534-9. PubMed ID: 23597418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-year follow-up using a prostate stent as fiducial in image-guided radiotherapy of prostate cancer.
    Carl J; Sander L
    Acta Oncol; 2015 Jun; 54(6):862-7. PubMed ID: 25539443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study.
    Di Muzio NG; Fodor A; Noris Chiorda B; Broggi S; Mangili P; Valdagni R; Dell'Oca I; Pasetti M; Deantoni CL; Chiara A; Berardi G; Briganti A; Calandrino R; Cozzarini C; Fiorino C
    Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):490-500. PubMed ID: 26961088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.
    Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-dimensional conformal arc radiotherapy using a C-arm linear accelerator with a computed tomography on-rail system for prostate cancer: clinical outcomes.
    Kumabe A; Fukuhara N; Utsunomiya T; Kawase T; Iwata K; Okada Y; Sutani S; Ohashi T; Oya M; Shigematsu N
    Radiat Oncol; 2015 Oct; 10():208. PubMed ID: 26458948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
    Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.
    Zelefsky MJ; Kollmeier M; Cox B; Fidaleo A; Sperling D; Pei X; Carver B; Coleman J; Lovelock M; Hunt M
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):125-9. PubMed ID: 22330997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-course, intensity-modulated radiotherapy for localized prostate cancer.
    Kupelian PA; Willoughby TR
    Cancer J; 2001; 7(5):421-6. PubMed ID: 11693901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
    Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionated radiotherapy for favorable risk prostate cancer.
    Rene N; Faria S; Cury F; David M; Duclos M; Shenouda G; Souhami L
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):805-10. PubMed ID: 20510194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
    Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Image-guided Intensity-modulated Radiotherapy for Prostate Cancer Employing Hypofractionation and Simultaneous Integrated Boost: Results of a Consecutive Case Series with Focus on Erectile Function.
    Girelli G; Franco P; Sciacero P; Cante D; Borca VC; Pasquino M; Annoscia S; Tofani S; La Porta MR; Ricardi U
    Anticancer Res; 2015 Jul; 35(7):4177-82. PubMed ID: 26124375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New methods in the treatment of localized prostate cancer: use of dynamic arc therapy and kV cone-beam CT positioning].
    Szappanos S; Farkas R; Lőcsei Z; László Z; Kalincsák J; Bellyei S; Sebestyén Z; Csapó L; Sebestyén K; Halász J; Musch Z; Beöthe T; Farkas L; Mangel L
    Orv Hetil; 2014 Aug; 155(32):1265-72. PubMed ID: 25087218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
    Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of margin reduction on late toxicity and short-term biochemical control for patients treated with daily on-line image guided IMRT for prostate cancer.
    Crehange G; Mirjolet C; Gauthier M; Martin E; Truc G; Peignaux-Casasnovas K; Azelie C; Bonnetain F; Naudy S; Maingon P
    Radiother Oncol; 2012 May; 103(2):244-6. PubMed ID: 22119374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer.
    Leborgne F; Fowler J; Leborgne JH; Mezzera J
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1200-7. PubMed ID: 21477933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.